Log in
NASDAQ:RUBY

Rubius Therapeutics Stock Forecast, Price & News

$4.59
-0.09 (-1.92 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.55
Now: $4.59
$4.78
50-Day Range
$4.61
MA: $5.08
$5.69
52-Week Range
$3.35
Now: $4.59
$14.44
Volume146,341 shs
Average Volume202,632 shs
Market Capitalization$370.73 million
P/E RatioN/A
Dividend YieldN/A
Beta1.99
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
Rubius Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RUBY
CUSIPN/A
CIKN/A
Phone617-679-9600
Employees142

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.44 per share

Profitability

Net Income$-163,460,000.00

Miscellaneous

Market Cap$370.73 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$4.59
-0.09 (-1.92 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RUBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions

How has Rubius Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Rubius Therapeutics' stock was trading at $6.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RUBY shares have decreased by 29.9% and is now trading at $4.59.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Rubius Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Rubius Therapeutics
.

When is Rubius Therapeutics' next earnings date?

Rubius Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Rubius Therapeutics
.

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics Inc (NASDAQ:RUBY) announced its quarterly earnings data on Monday, August, 10th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.50) by $0.03.
View Rubius Therapeutics' earnings history
.

What price target have analysts set for RUBY?

5 brokers have issued 12-month price objectives for Rubius Therapeutics' shares. Their forecasts range from $4.00 to $28.00. On average, they anticipate Rubius Therapeutics' stock price to reach $11.20 in the next twelve months. This suggests a possible upside of 144.0% from the stock's current price.
View analysts' price targets for Rubius Therapeutics
.

Who are some of Rubius Therapeutics' key competitors?

What other stocks do shareholders of Rubius Therapeutics own?

Who are Rubius Therapeutics' key executives?

Rubius Therapeutics' management team includes the following people:
  • Mr. David R. Epstein, Exec. Chairman (Age 57)
  • Dr. Christopher L. Carpenter M.D., Ph.D., Chief Medical Officer (Age 63)
  • Dr. Pablo J. Cagnoni, CEO, Pres & Director (Age 56)
  • Mr. Andrew M. Oh, Chief Financial Officer (Age 47)
  • Ms. Joanne M. Protano, Sr. VP of Fin. & Operations (Age 50)

When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include NEXT Financial Group Inc (0.01%). Company insiders that own Rubius Therapeutics stock include Christina M Coughlin, Christopher L Carpenter, David R Epstein, Pablo J Cagnoni, Robert Langer and Torben Straight Nissen.
View institutional ownership trends for Rubius Therapeutics
.

Which major investors are buying Rubius Therapeutics stock?

RUBY stock was bought by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc. Company insiders that have bought Rubius Therapeutics stock in the last two years include Christina M Coughlin, David R Epstein, and Pablo J Cagnoni.
View insider buying and selling activity for Rubius Therapeutics
.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $4.59.

How big of a company is Rubius Therapeutics?

Rubius Therapeutics has a market capitalization of $370.73 million. The company earns $-163,460,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Rubius Therapeutics employs 142 workers across the globe.

What is Rubius Therapeutics' official website?

The official website for Rubius Therapeutics is www.rubiustx.com.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.